Showing 7411-7420 of 8825 results for "".
- It's Going to Be a Scorcher: Experts Predict Extreme UV Index Ratings This Memorial Dayhttps://practicaldermatology.com/news/its-going-to-be-a-scorcher-experts-predict-extreme-uv-index-ratings-this-memorial-day/2461739/A dozen U.S. cities are expected to have extreme ultraviolet (UV) index ratings (10+) this Memorial Day and throughout the summer, according to data from the
- FDA Nod for Cyltezo Autoinjector Penhttps://practicaldermatology.com/news/fda-nod-for-cyltezo-autoinjector-pen/2461738/The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm). Cyltezo is an FDA-approved interchangeable biosimilar to Humira (adalimumab). Initially approved as a pre
- Wayne State University Dermatology Resident Wins Svider Memorial Scholarship Awardhttps://practicaldermatology.com/news/wayne-state-university-dermatology-resident-wins-svider-memorial-scholarship-award/2461737/Kayla St. Claire, M.D., M.B.A., a Wayne State University School of Medicine dermatology resident, has won the Peter Svider Memorial Resident Scholarship Award. The award is presented annually to a graduating resident or fellow in any graduate medical education program in recognition of
- First Patient Dosed in TrialSpark's Phase 2 Trial of ASN008-201 in ADhttps://practicaldermatology.com/news/first-patient-dosed-in-trailsparks-phase-2-trial-of-asn008-201-in-ad/2461736/The first patient has been dosed in TrialSpark’s Phase 2 clinical trial for ASN008-201, a topical sodium channel blocker in development for pruritus associated with atopic dermatitis (AD). This clinical trial is a randomized, double-blind, vehicle-controlled, Phase 2 tr
- FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with DEBhttps://practicaldermatology.com/news/fda-approves-first-topical-gene-therapy-for-treatment-of-wounds-in-patients-with-deb/2461732/The U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) g
- EltaMD Teams Up With Bravo's Andy Cohen for Skin Cancer Awarenesshttps://practicaldermatology.com/news/eltamd-teams-up-with-bravos-andy-cohen-for-skin-cancer-awareness/2461729/EltaMD has partnered with Andy Cohen and the Melanoma Research Foundation on a social campaign aimed to ignite dialogue surrounding skin cancer, while educating consumers on the importance of skin checks for National Skin Cancer Awareness Month. As part of this initiative, and to encour
- Dr. David Simon Wins Pershing Square Sohn Prize for Young Investigators in Cancer Research to Study Melanomahttps://practicaldermatology.com/news/dr-david-simon-wins-pershing-square-sohn-prize-for-young-investigators-in-cancer-research-to-studying-melanoma/2461722/Dr. David Simon has won the Pershing Square Sohn Prize for Young Investigators in Cancer Research to study melanoma. Dr. Simon is the Fernholz Foundation Research Scholar in Neuroscience and an a
- FDA Greenlights Phio Pharmaceuticals' Trial of PH-762 in Skin Cancerhttps://practicaldermatology.com/news/fda-greenlights-phio-pharmaceuticals-trial-of-ph-762-in-skin-cancer/2461721/The U.S. Food and Drug Administration (FDA) has cleared Phio Pharmaceuticals’ Investigational New Drug (IND) application to move ahead with a clinical trial of PH-762 for treating skin cancer. PH-762 is an INTASYL compound
- First Subject Dosed in Phase 1 Clinical Study of NM26 for ADhttps://practicaldermatology.com/news/first-subject-dosed-in-phase-1-clinical-study-of-nm26-for-ad/2461718/The first subject has been dosed in the Phase 1 clinical study of Numab Therapeutics’ NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). This marks the beginning of a combined single ascending dose (SAD) and multip
- Skinvive by Juvéderm Scores FDA Nod to Improve Skin Smoothness in Cheekshttps://practicaldermatology.com/news/skinvive-by-juvederm-scores-fda-nod-to-improve-skin-smoothness-in-cheeks/2461717/The U.S. Food and Drug Administration gave its nod to Skinvive by Juvéderm to improve skin smoothness of the cheeks in adults over the age of 21. Skinvive by Juvéderm is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness availabl